Author:
Johnson Sindhu R.,Van den Hoogen Frank H. J.,Domsic Robyn T.
Publisher
Springer International Publishing
Reference103 articles.
1. Block JA, Sequeira W. Raynaud’s phenomenon. Lancet. 2001;357(9273):2042–8. https://doi.org/10.1016/S0140-6736(00)05118-7.
2. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–5.
3. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36(2):323–9. https://doi.org/10.3899/jrheum.071169.
4. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–8. https://doi.org/10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I.
5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66. https://doi.org/10.1056/NEJMoa055120.